PCVX
Vaxcyte, Inc. Common Stock
stockNASDAQ
sutrovax is a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases. sutrovax's lead product candidate is a pneumococcal conjugate vaccine (pcv) that is designed to prevent invasive pneumococcal disease (ipd) caused by streptococcus pneumoniae. sutrovax's broad-spectrum pcv is designed to provide expanded protection against circulating strains of pneumococcus and has the potential to replace the current vaccines used in infants and adults. the current mainstay vaccine only covers approximately 40% of the circulating strains causing ipd yet generates $6b in annual sales. sutrovax has generated positive pre-clinical proof-of-concept with its significantly broader-spectrum pcv compared head-to-head to current vaccines using well accepted immunological endpoints. in addition to its lead pcv product candidate, the company also has a promising early-stage pipeline addressing othe
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 58.27 | 2026-09-28 | +31.30% | 1.930 |
| 1M | 61.16 | 2026-09-04 | +25.10% | 1.174 |
| 3M | 56.96 | 2026-07-06 | +34.32% | 0.946 |
| 6M | 59.82 | 2026-04-06 | +27.90% | 0.781 |
| 1Y | 41.21 | 2025-10-06 | +85.66% | 0.849 |
| 2Y | 111.29 | 2024-10-04 | -31.25% | — |
| 5Y | 24.12 | 2021-10-05 | +217.21% | 0.816 |
Vaxcyte, Inc. Common Stock (NASDAQ:PCVX) stock price today is $76.51, and today's volume is 5,426,803. PCVX is up 35.465% today. The 30 day average volume is 1.34M. PCVX market cap is $11.39B with 148.81M shares outstanding.